MCMs in Cancer: Prognostic Potential and Mechanisms

Table 2

Prognostic roles of the MCM proteins in different types of cancer.

Subunit	Tumor types	References
Negative correlation between MCM expression level and prognostic outcomes
MCM2	Lung squamous cell carcinoma, glioma, muscle-invasive urothelial bladder carcinomas, ovarian adenocarcinomas, prostate cancer, diffuse large B-cell lymphoma, salivary gland tumor, hepatocellular carcinoma, gastric cardiac cancer	[26], [82], [67], [37], [83], [84], [46], [53], [54]
MCM3	Glioma, oral squamous cell carcinoma, cutaneous T-cell lymphomas	[82], [44], [85]
MCM4	Laryngeal squamous cell carcinoma	[38]
MCM5	Lung squamous cell carcinoma, muscle-invasive urothelial bladder carcinomas, ovarian adenocarcinomas	([37, 67, 70]
MCM6	Glioma, hepatocellular carcinoma	[33], ([86]; [87])
MCM7	Colorectal cancer, glioma, oral squamous cell carcinoma, laryngeal squamous cell carcinoma, diffuse-type gastric adenocarcinoma, papillary urothelial neoplasia	[77], [82], [68], [88], [43], [39]
MCM8	Pancreatic cancer	[31]
MCM10	Breast cancer, hepatocellular carcinoma, urothelial carcinoma	[56], ([53]; [69]), [57]
Positive correlation between MCM expression level and prognostic outcomes
MCM2	ER-positive breast cancer, colorectal cancer	[73], [89]
MCM6	Hodgkin’s lymphoma	[71]
MCM7	Small lung adenocarcinomas	[66]
Not qualified to be an independent prognostic marker
MCM2	Colorectal cancer, squamous cell carcinoma of the penis, non-small-cell lung cancer, medulloblastoma	[77], [76], [78], [50]